AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Florida Panthers Even Stanley Cup Final Series with Edmonton Oilers
ByAinvest
Saturday, Jun 7, 2025 12:58 am ET1min read
Immix Biopharma's NXC-201 achieved a 70% complete response rate in its NEXICART-2 Phase 1/2 trial for relapsed/refractory AL Amyloidosis. The therapy demonstrated a strong safety profile with no neurotoxicity and improved cardiac and renal functions in all patients. Immix Biopharma plans to submit a Biologics License Application for FDA approval.
Immix Biopharma, Inc. (NASDAQ:IMMX) has reported promising results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201, a cell therapy for relapsed/refractory AL amyloidosis. The trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025), achieved a 70% complete response (CR) rate, surpassing the typical CR rate of less than 10% for existing treatments [1, 2].NXC-201 demonstrated a strong safety profile, with no neurotoxicity and only low-grade cytokine release syndrome observed. The therapy also improved cardiac and renal functions in all patients, suggesting significant clinical benefits [1, 2].
Immix Biopharma plans to submit a Biologics License Application (BLA) for FDA approval following the successful trial results. The company is preparing for a Key Opinion Leader (KOL) event to discuss the implications of these findings on Tuesday, June 3, 2025, at 3:00 pm ET [1, 2].
The trial involved ten patients and met its primary endpoint with a CR rate of 70%. No relapses have been recorded to date, indicating the potential of NXC-201 as a viable treatment option for this severe condition. The results underscore the therapy's efficacy and safety profile, positioning it favorably in a market with limited FDA-approved agents [1, 2].
Investors and financial professionals should closely monitor Immix Biopharma's progress as it moves towards FDA approval and potential commercialization of NXC-201. The company's stock has seen recent insider and institutional activity, suggesting interest in the company's prospects [1, 2].
References:
[1] https://finance.yahoo.com/news/h-c-wainwright-reiterates-buy-203346352.html
[2] https://www.nasdaq.com/articles/immix-biopharma-reports-70-complete-response-rate-nxc-201-phase-1-2-al-amyloidosis-trial
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet